An open-label phase I dose-finding study of APR-246 in hematological malignancies

Blood Cancer J. 2016 Jul 15;6(7):e447. doi: 10.1038/bcj.2016.60.
No abstract available

Publication types

  • Clinical Trial, Phase I
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / adverse effects
  • Dose-Response Relationship, Drug
  • Female
  • Hematologic Neoplasms / drug therapy*
  • Hematologic Neoplasms / pathology
  • Humans
  • Male
  • Maximum Tolerated Dose
  • Middle Aged
  • Quinuclidines / administration & dosage*
  • Quinuclidines / adverse effects
  • Treatment Outcome

Substances

  • 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one
  • Antineoplastic Agents
  • Quinuclidines